GSK has built the case for first-line use of its PD-1 inhibitor Jemperli in endometrial cancer, with new survival data that could help it expand the label for the drug.
Amid all the new high-tech therapies on display at the ESMO cancer conference, a study funded by Cancer Research UK has shown what can be achieved with cheap generic drugs
In the last decade, immunotherapy with PD-1/PD-L1 inhibitors has transformed the treatment of relapsed urothelial carcinoma (UC), the most common form of bladder cancer.
Just days after MSD claimed an FDA approval for Keytruda as a pre- and post-surgery option for early non-small cell lung cancer (NSCLC), Bristol-Myers Squibb has staked a
Daiichi Sankyo’s antibody-drug conjugate (ADC) franchise has generated another massive licensing deal, this time from MSD, which is paying $4 billion upfront for rights to
MSD’s Keytruda has become the first immunotherapy in the US that can be used continuously, before and after surgery, in patients with early-stage non-small cell lung cance